This study tests a new medicine called enlicitide decanoate, which is a PCSK9 inhibitor. PCSK9 inhibitors are drugs that help lower bad cholesterol and are taken by mouth. The study checks if this medicine can help people with high cardiovascular risk avoid serious heart problems like heart attacks or strokes. Participants will either receive the medicine or a placebo, which is a pill that looks like the medicine but has no effect, to compare results.

Key Points:

• Participants must be 18 or older, with a history of heart disease or at risk for it, and currently taking certain cholesterol medicines.
• The study will involve regular visits and tests to monitor health and cholesterol levels.
• Participants will be randomly assigned to receive either the new drug or a placebo, not knowing which one they get.

Before joining, make sure you meet the health criteria and understand the commitment involved. The study will assess if this new treatment can effectively reduce major heart issues. Always discuss with your doctor to ensure it's a good fit for you.